Alector [ALEC] vs Silence Therapeutics [SLN] Detailed Stock Comparison
Alector
NASDAQ
Loading...
Silence Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Alector wins in 9 metrics, Silence Therapeutics wins in 8 metrics, with 0 ties. Alector appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alector | Silence Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.13 | -4.86 | Silence Therapeutics |
| Price-to-Book Ratio | 3.34 | 2.41 | Silence Therapeutics |
| Debt-to-Equity Ratio | 55.47 | 0.00 | Silence Therapeutics |
| PEG Ratio | 0.09 | -0.14 | Silence Therapeutics |
| EV/EBITDA | 0.24 | -7.96 | Silence Therapeutics |
| Profit Margin (TTM) | -142.10% | -291.24% | Alector |
| Operating Margin (TTM) | -433.55% | -9,048.21% | Alector |
| Return on Equity | -103.99% | -66.96% | Silence Therapeutics |
| Return on Assets (TTM) | -17.84% | -22.25% | Alector |
| Free Cash Flow (TTM) | $-231.16M | $-67.85M | Silence Therapeutics |
| 1-Year Return | -55.49% | -74.80% | Alector |
| Price-to-Sales Ratio (TTM) | 2.93 | 8.36 | Alector |
| Enterprise Value | $-29.95M | $567.43M | Silence Therapeutics |
| EV/Revenue Ratio | -0.37 | 20.89 | Alector |
| Gross Profit Margin (TTM) | N/A | 62.05% | N/A |
| Revenue per Share (TTM) | $1 | $1 | Alector |
| Earnings per Share (Diluted) | $-1.16 | $-1.68 | Alector |
| Beta (Stock Volatility) | 0.86 | 1.39 | Alector |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Alector vs Silence Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alector | -1.67% | -6.75% | 45.96% | 65.49% | 43.29% | 24.34% |
| Silence Therapeutics | -5.69% | -10.09% | -22.42% | -19.02% | 6.89% | -33.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alector | -55.49% | -77.53% | -81.06% | -85.58% | -85.58% | -85.58% |
| Silence Therapeutics | -74.80% | -54.58% | -75.33% | -75.33% | -75.33% | -75.33% |
Performance & Financial Health Analysis: Alector vs Silence Therapeutics
| Metric | ALEC | SLN |
|---|---|---|
| Market Information | ||
| Market Cap | $139.71M | $203.97M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 943,720 | 41,090 |
| 90 Day Avg. Volume | 1,262,570 | 65,773 |
| Last Close | $2.35 | $4.81 |
| 52 Week Range | $0.87 - $6.37 | $1.97 - $20.48 |
| % from 52W High | -63.11% | -76.51% |
| All-Time High | $43.32 (Jun 28, 2021) | $35.00 (May 24, 2021) |
| % from All-Time High | -94.58% | -86.26% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.48% | -0.70% |
| Quarterly Earnings Growth | -0.48% | -0.70% |
| Financial Health | ||
| Profit Margin (TTM) | -1.42% | -2.91% |
| Operating Margin (TTM) | -4.34% | -90.48% |
| Return on Equity (TTM) | -1.04% | -0.67% |
| Debt to Equity (MRQ) | 55.47 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.70 | $1.99 |
| Cash per Share (MRQ) | $3.04 | $0.81 |
| Operating Cash Flow (TTM) | $-215,591,008 | $-87,181,000 |
| Levered Free Cash Flow (TTM) | $-98,126,376 | $-39,052,924 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Alector vs Silence Therapeutics
| Metric | ALEC | SLN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.13 | -4.86 |
| Forward P/E | -1.59 | -6.41 |
| PEG Ratio | 0.09 | -0.14 |
| Price to Sales (TTM) | 2.93 | 8.36 |
| Price to Book (MRQ) | 3.34 | 2.41 |
| Market Capitalization | ||
| Market Capitalization | $139.71M | $203.97M |
| Enterprise Value | $-29,948,026 | $567.43M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.37 | 20.89 |
| Enterprise to EBITDA | 0.24 | -7.96 |
| Risk & Other Metrics | ||
| Beta | 0.86 | 1.39 |
| Book Value per Share (MRQ) | $0.70 | $1.99 |
Financial Statements Comparison: Alector vs Silence Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALEC | SLN |
|---|---|---|
| Revenue/Sales | $3.67M | $224,000 |
| Cost of Goods Sold | N/A | $85,000 |
| Gross Profit | N/A | $139,000 |
| Research & Development | $33.64M | $17.65M |
| Operating Income (EBIT) | $-44.70M | $-22.64M |
| EBITDA | $-42.85M | $-14.55M |
| Pre-Tax Income | $-40.47M | $-27.34M |
| Income Tax | $0 | $10,000 |
| Net Income (Profit) | $-40.47M | $-27.35M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALEC | SLN |
|---|---|---|
| Cash & Equivalents | $37.97M | $41.74M |
| Total Current Assets | $366.65M | $148.55M |
| Total Current Liabilities | $109.77M | $14.77M |
| Long-Term Debt | $32.22M | N/A |
| Total Shareholders Equity | $94.61M | $94.16M |
| Retained Earnings | $-869.60M | $-529.84M |
| Property, Plant & Equipment | $35.29M | $1.83M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALEC | SLN |
|---|---|---|
| Operating Cash Flow | $-48.49M | $-25.24M |
| Capital Expenditures | $-20,000 | $-48,000 |
| Free Cash Flow | $-60.80M | $-21.83M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALEC | SLN |
|---|---|---|
| Shares Short | 5.47M | 770,450 |
| Short Ratio | 4.42 | 9.84 |
| Short % of Float | 0.07% | 0.02% |
| Average Daily Volume (10 Day) | 943,720 | 41,090 |
| Average Daily Volume (90 Day) | 1,262,570 | 65,773 |
| Shares Outstanding | 99.09M | 141.67M |
| Float Shares | 84.72M | 74.75M |
| % Held by Insiders | 0.10% | 0.24% |
| % Held by Institutions | 0.77% | 0.44% |
Dividend Analysis & Yield Comparison: Alector vs Silence Therapeutics
| Metric | ALEC | SLN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |